These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26926631)

  • 1. Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.
    Rojo-Molinero E; Macià MD; Rubio R; Moyà B; Cabot G; López-Causapé C; Pérez JL; Cantón R; Oliver A
    Antimicrob Agents Chemother; 2016 May; 60(5):2912-22. PubMed ID: 26926631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
    Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
    Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
    Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA
    J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
    Kirby BD; Al Ahmar R; Withers TR; Valentine ME; Valentovic M; Long TE; Gaskins JR; Yu HD
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010865
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.
    Riera E; Macià MD; Mena A; Mulet X; Pérez JL; Ge Y; Oliver A
    J Antimicrob Chemother; 2010 Jul; 65(7):1399-404. PubMed ID: 20435779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa.
    Alipour M; Dorval C; Suntres ZE; Omri A
    J Pharm Pharmacol; 2011 Aug; 63(8):999-1007. PubMed ID: 21718282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
    Furiga A; Lajoie B; El Hage S; Baziard G; Roques C
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Biofilm Antimicrobial Activity of Polyethylene Glycol Conjugated Tobramycin Compared to Tobramycin in Pseudomonas aeruginosa Biofilms.
    Du J; Bandara HM; Du P; Huang H; Hoang K; Nguyen D; Mogarala SV; Smyth HD
    Mol Pharm; 2015 May; 12(5):1544-53. PubMed ID: 25793309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
    Mulet X; Maciá MD; Mena A; Juan C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1552-60. PubMed ID: 19188376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells.
    Moreau-Marquis S; Coutermarsh B; Stanton BA
    J Antimicrob Chemother; 2015 Jan; 70(1):160-6. PubMed ID: 25213272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
    Agyeman AA; López-Causapé C; Rogers KE; Lucas DD; Cortés-Lara S; Gomis-Font MA; Fraile-Ribot P; Figuerola J; Lang Y; Franklyn ERT; Lee WL; Zhou J; Zhang Y; Bulitta JB; Boyce JD; Nation RL; Oliver A; Landersdorfer CB
    Int J Antimicrob Agents; 2023 Sep; 62(3):106887. PubMed ID: 37315906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR; White A; Elborn JS; Tunney MM
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
    Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms.
    Nagant C; Tré-Hardy M; El-Ouaaliti M; Savage P; Devleeschouwer M; Dehaye JP
    Appl Microbiol Biotechnol; 2010 Sep; 88(1):251-63. PubMed ID: 20625718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 19. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
    Plasencia V; Borrell N; Maciá MD; Moya B; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2574-81. PubMed ID: 17470655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media.
    Thellin O; Zorzi W; Jolois O; Elmoualij B; Duysens G; Cahay B; Streel B; Charif M; Bastin R; Heinen E; Quatresooz P
    Int J Antimicrob Agents; 2015 Jul; 46(1):33-8. PubMed ID: 25963337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.